Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Disease 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

atezolizumab 3Etoposide 2Cisplatin 2veliparib 1tivozanib 1surufatinib 1repotrectinib 1pralsetinib 1pembrolizumab 1durvalumab 1berzosertib 1avelumab 1Topotecan 1Podophyllotoxin 1Platinum 1Paclitaxel 1Nivolumab 1Ipilimumab 1Everolimus 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Neuroendocrine × tivozanib × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡